Archives

Accent Therapeutics to Present Preclinical Data on Lead Clinical Program, ATX-295, at the 2026 American Association for Cancer Research Annual Meeting

B Findings reinforce the multi-tumor potential of KIF18A inhibitor, ATX-295, in high-grade serous ovarian, squamous non-small cell lung, and triple-negative breast cancer models LEXINGTON, Mass., April 2, 2026 /PRNewswire/ —…

Read MoreAccent Therapeutics to Present Preclinical Data on Lead Clinical Program, ATX-295, at the 2026 American Association for Cancer Research Annual Meeting

Cambridge Global Advisors Awarded Grant to Build Cyber Capacity Among Women in the Pacific from Australia’s Department of Foreign Affairs and Trade

B WASHINGTON, April 2, 2026 /PRNewswire/ — Australia’s Department of Foreign Affairs and Trade (DFAT) has partnered with Cambridge Global Advisors (CGA) to implement a comprehensive cybersecurity capacity-building initiative centered…

Read MoreCambridge Global Advisors Awarded Grant to Build Cyber Capacity Among Women in the Pacific from Australia’s Department of Foreign Affairs and Trade

Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026

B Oral semaglutide 25 mg demonstrated significantly greater mean weight loss than orforglipron 36 mg in a population-adjusted indirect treatment comparison (ITC) using data from the OASIS 4 and ATTAIN-1…

Read MoreWegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026